ICR welcomes FDA approval of first-in-class breast cancer drug 17 Nov 2023 The ICR strongly welcomes the news that a new targeted drug, capivasertib, has been approved by the US FDA for treating the most common type of advanced breast cancer. The drug was discovered by pharmaceutical company AstraZeneca following a programme of drug discovery research at the ICR in collaboration with Astex Pharmaceuticals. Find out more Show/Hide
Profiling gene messages could guide chemotherapy for triple negative breast cancer 13 Aug 2023 A new study sheds light on the genetic messages encoded by genes within ‘triple negative’ breast cancers – and poses important questions on how they could be better treated in future. Find out more Show/Hide
Gene test could guide use of cancer chemotherapy 02 Mar 2023 A gene test already used routinely in the NHS can guide use of chemotherapy in people with bowel cancer by predicting whether or not they will benefit. Find out more Show/Hide
All patients’ cancers should be genetically profiled to improve care, say leading health experts 08 Aug 2022